Baidu
map

乳腺癌诊疗指南(2022年版)

2022-04-11 中华人民共和国国家卫生健康委员会 中华人民共和国国家卫生健康委员会官网

为进一步规范我国乳腺癌诊疗行为,提高医疗机构乳腺癌诊疗水平,改善乳腺癌患者预后,保障医疗质量和医疗安全,特制定本指南。

中文标题:

乳腺癌诊疗指南(2022年版)

发布日期:

2022-04-11

简要介绍:

乳腺癌是女性常见的恶性肿瘤之一,发病率位居女性恶性肿瘤的首位,严重危害妇女的身心健康。目前,通过采用综合治疗手段,乳腺癌已成为疗效最佳的实体肿瘤之一。为进一步规范我国乳腺癌诊疗行为,提高医疗机构乳腺癌诊疗水平,改善乳腺癌患者预后,保障医疗质量和医疗安全,特制定本指南。

相关资料下载:
[AttachmentFileName(sort=1, fileName=乳腺癌诊疗指南+(2022年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=2d53a1c00250989b, title=乳腺癌诊疗指南(2022年版), enTitle=, guiderFrom=中华人民共和国国家卫生健康委员会官网, authorId=0, author=, summary=为进一步规范我国乳腺癌诊疗行为,提高医疗机构乳腺癌诊疗水平,改善乳腺癌患者预后,保障医疗质量和医疗安全,特制定本指南。, cover=https://img.medsci.cn/Random/diagnostic-form-in-hospital-conceptual-image-7JAH3GT.jpg, journalId=0, articlesId=null, associationId=1653, associationName=中华人民共和国国家卫生健康委员会, associationIntro=, copyright=0, guiderPublishedTime=Mon Apr 11 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">乳腺癌是女性常见的恶性肿瘤之一,发病率位居女性恶性肿瘤的首位,严重危害妇女的身心健康。目前,通过采用综合治疗手段,乳腺癌已成为疗效最佳的实体肿瘤之一。为进一步规范我国乳腺癌诊疗行为,提高医疗机构乳腺癌诊疗水平,改善乳腺癌患者预后,保障医疗质量和医疗安全,特制定本指南。</span></p>, tagList=[TagDto(tagId=72213, tagName=国家卫健委), TagDto(tagId=440210, tagName=乳腺癌诊疗指南)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21054, categoryName=梅斯医学-乳腺癌网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=285, articleKeyword=乳腺癌, articleKeywordNum=6, guiderKeywordId=308, guiderKeyword=诊疗指南, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=18969, appHits=684, showAppHits=0, pcHits=2530, showPcHits=18284, likes=0, shares=95, comments=4, approvalStatus=1, publishedTime=Tue Jul 12 20:35:00 CST 2022, publishedTimeString=2022-04-11, pcVisible=1, appVisible=1, editorId=0, editor=lixiang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=7, createdBy=null, createdName=lixiang, createdTime=Thu Jul 07 17:06:42 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Sat Jan 06 18:43:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=乳腺癌诊疗指南+(2022年版).pdf)])
乳腺癌诊疗指南+(2022年版).pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2024-09-18 ms6000000190242997 来自湖北省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-17 海上飘星

    好好学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-15 ms5000000275821148

    下载来学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-12 ms2000000529313829

    学习

    0

拓展阅读

85.7%的PTEN胚系突变女性罹患乳腺癌,具有怎样的临床病理和分子特征?

本研究的优势包括对这些女性乳腺癌患病情况独特的长期观察。遗憾的是,由于研究的时间跨度长,大多数病例的原始玻片和组织蜡块无法无法获取以供审查。本文提供的数据基于原始病理报告。

2024 JINBCS | 刘慧教授:HER2+乳腺癌治疗痛点和新进展分享

特邀请河南省人民医院刘慧教授分享HER2+乳腺癌治疗现状及最新前沿进展。

聚焦前沿热点,共创未来发展——第四届天津国际乳腺癌大会成功举办

12月20日,由中国抗癌协会主办,天津医科大学肿瘤医院、国家恶性肿瘤临床医学研究中心共同承办的第四届天津国际乳腺癌大会在滨海新区召开。

【中西合璧】针刺对慢性神经性疼痛的调节及其与脑功能特性的关系—针刺对神经性疼痛的影响

在标准三联止吐治疗的基础上加入真电针,可显著提高接受HEC治疗的乳腺癌患者CINV治疗的疗效。

HER2阳性乳腺癌按FISH结果细分,靶向治疗获益分层

这些发现提供了有价值的关于不同 HER2 FISH 阳性亚组的临床病理学见解,可能为未来解读 HER2 FISH 结果的标准提供信息。

会议预告丨2024天津国际乳腺癌大会(12.18-12.21)

天津国际乳腺癌大会将于2024年12月18日至21日在历史悠久而又充满活力的滨海之都天津盛大召开。本次大会以“健康同行创未来,携手同彩映前程”为主题,旨在汇聚全球前瞻医学智慧,共绘乳腺肿瘤防治新篇章。

2022 BAD/BPG指南:窄谱中波紫外线光疗

英国皮肤科医师协会(BAD,British Association of Dermatologists) · 2022-05-23

2020 ECCO/ESPGHAN指南:儿童克罗恩病的药物治疗

欧洲克罗恩病和结肠炎组织(ECCO,European Cron&#039;s and Colitis Organisation) · 2020-10-07

中国乳腺癌筛查与早期诊断指南

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2022-04-28

2020 AAO指南:成人眼科综合评估

美国眼科学会(AAO,American Academy of Ophthalmology) · 2020-11-30

疟疾诊疗指南

浙江大学医学院附属第一医院 · 2022-07-29

ESC和ACC/AHA/HFSA心力衰竭指南的建议之间的头对头比较

欧洲心脏病学会(ESC,European Society of Cardiology) · 2022-08-25

Baidu
map
Baidu
map
Baidu
map